Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Cutting-Edge Concepts in HIV Care: Long-Acting Therapies

Listen to Paul E. Sax, MD, discuss what’s new in long-acting injectables for HIV treatment.
Paul E. Sax, MD
Released: November 14, 2022

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:

  • Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
  • Risk factors for virologic failure of LA CAB + RPV
  • The ATLAS-2M study
  • Combined clinical trials of LA CAB + RPV
  • Practical considerations for LA CAB + RPV
  • Implementation of LA CAB + RPV
  • Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
  • Supporting candidates for LA antiretroviral therapy (ART)
  • Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
  • Future LA ART
  • The investigational LA HIV capsid inhibitor lenacapavir (LEN)
  • LEN resistance from the CAPELLA and CALIBRATE studies
  • LEN injection-site reactions in the CAPELLA and CALIBRATE studies

Information on this Educational Activity


Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen; researcher: Gilead Sciences, GlaxoSmithKline/ViiV Healthcare.

Program Medium

This program has been made available online.


Jointly provided by the Association of Nurses in AIDS Care and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings